Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07675811 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy

StatusRecruiting
PhasePhase 3
Started2026-07-31
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 19 months later Oct 16, 2027 → May 31, 2029
See other at-risk trials from Regeneron

Amendment history

2026-08-10
Study Status, Contacts/Locations v1
Recruitment opened
Primary completion pushed: 2027-10-16 → 2029-05-31
Completion pushed: 2028-06-30 → 2029-09-20
Start dateestimated 2026-07-27→confirmed 2026-07-31
Study sites0→1
2026-06-23
Original filing
Regeneron
148 trials monitored
See 16 trials at risk
This study is researching two experimental medicines, freneslerbart and mevonlerbart. Freneslerbart and mevonlerbart can be given alone or together. When given together, the medicine is called "REGN-2Cat". These medicines are also known as the "study drugs". The aim of the study is to see what side effects freneslerbart, mevonlerbart, and REGN-2Cat may have and if they help reduce eye allergy symptoms caused by cat hair/dander compared with a placebo. The study is looking at several other research questions, including: * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) * How long the study drug effect lasts
Trial Details
NCT Number NCT07675811
Lead Sponsor Regeneron Pharmaceuticals
Conditions Allergic Conjunctivitis
Enrollment 570 participants
Start Date 2026-07-31
Primary Completion 2029-05-31 (estimated)
Study Completion 2029-09-20 (estimated)
Updated on ClinicalTrials.gov 2026-08-12